Trial Evaluating Cardiovascular Outcomes With Sitagliptin
TECOS is seeking ancillary study proposals...
The Executive Committee for the Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) will accept ancillary study proposals for review. Ancillary studies may provide valuable information beyond that explored in the context of the main trial, and will promote continued academic interest in TECOS.
TECOS poster presentation
The TECOS poster entitled "Rationale & Design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)" was presented on Sept 30th by Dr M. Angelyn Bethel at the European Association for the Study of Diabetes (EASD) international conference in Vienna.
TECOS launched in Europe
TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) launched in Europe in June and has recruited 30 participants to date from Hungary, Lithuania & Spain.
Centres in India, South Africa and Canada are now open and are expected to start recruiting shortly.
First 100 patients enrolled into TECOS
TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) has been recruiting patients in the United States since December 2008 and with nearly 100 patients already randomised, TECOS is now about to begin recruitment across a number of countries around the world.
Since early 2009 the Duke Clinical Research Institute (DCRI) and the Diabetes Trials Unit, University of Oxford (DTU) have hosted a number of training days (Investigator Meetings) for new clinical sites in North America, India and Europe, and will be launching the trial in the Asia/Pacific regions over the Summer....